BD is preparing a major expansion of its U.S. operations, adding to a growing list of healthcare companies increasing manufacturing commitments to the U.S. Unlike many recent pharmaceutical investments, BD’s plan is centered on medical devices and the everyday supplies relied upon by clinicians and patients.
The company said on October 6 that it expects to commit $19 billion to the U.S. over a few years through capital spending, operating investments and supply-chain initiatives. About $3 billion of that total will go toward expanding BD manufacturing facilities located around the country.
BD already operates production facilities in states including South Carolina, Texas, Nebraska, Utah, Georgia and Connecticut, in addition to Puerto Rico. Its portfolio spans a broad range of healthcare products, including syringes, catheters, endoscope systems and implantable mesh.
BD CEO Tom Polen said the agreement with the U.S. government demonstrates a joint effort to reinforce healthcare infrastructure, increase domestic manufacturing capacity and maintain dependable access to critical medical technologies. He said the goal is ultimately to create a healthcare supply network that is more resilient over the long term.
Once the planned upgrades are operational, BD expects its U.S. facilities to add approximately 5 billion essential medical consumables to annual domestic production. The company believes that increase could raise the proportion of its consumables supplied from within the U.S. to around 80%.
BD also said it intends to manufacture domestically all of the products it needs for the U.S. market, using steel produced in the country.
The agreement also includes protection from future Section 232 tariffs for applicable BD products, similar to arrangements recently reached between the federal government and pharmaceutical manufacturers under the so-called “most favored nation” framework.
According to BD, the tariff relief should provide greater predictability for long-term manufacturing and supply-chain decisions. However, the company is not yet estimating the financial benefit because the final tariff rates, implementation schedule and products covered by the measures have not been determined.
Polen said the administration understands the need for a more resilient healthcare supply chain, adding that BD’s manufacturing presence, scale and innovation capabilities position the company to support that objective.
BD’s announcement comes amid a broader push by healthcare companies to expand manufacturing in the U.S. since the Trump administration returned to office.
In pharmaceuticals, 26 large and mid-sized drugmakers have entered “most favored nation” agreements with the White House. The arrangements pair commitments involving U.S. investment and drug pricing with exemptions from certain trade duties on their medicines.
Bayer has also announced a major domestic manufacturing project. The German company said Friday that it plans to spend over $2 billion on a new advanced facility in Ohio, which is expected to employ about 600 people once fully operational. The plant will initially manufacture products serving oncology, cardiovascular and renal care.
Bayer’s investment supports the administration’s effort to bring more production onto U.S. soil, but Sebastian Guth, Bayer’s U.S. president, said the project should be viewed as Bayer’s increasingly strong emphasis on the U.S. market.
BD Plans Major Investment in U.S. Medical Manufacturing
BD, also known as Becton, Dickinson and Company, is expanding its commitment to U.S. manufacturing as healthcare organizations increasingly prioritize reliable supplies, resilient production networks, and access to essential technologies.
The company’s investment plans reflect a broader trend across the Medical technology industry, where manufacturers are strengthening domestic production capabilities to meet healthcare demand and reduce supply chain vulnerabilities. Investments in manufacturing facilities can help companies improve production efficiency, modernize equipment, and support the availability of products used by hospitals, laboratories, and other healthcare providers.
For BD, expanding U.S. manufacturing capabilities also aligns with the importance of maintaining dependable production systems for devices and supplies that support everyday patient care.
Strengthening Domestic Medical Supply Chains
Healthcare providers rely on a complex network of manufacturers, suppliers, distributors, and logistics companies to maintain access to essential products. Disruptions affecting any part of this network can create challenges for hospitals and clinical facilities.
In addition, companies must ensure that expanded operations maintain consistent quality across different facilities. Effective planning and investment in workforce capabilities will be important for turning manufacturing expansion into dependable production output.
The Future of U.S. Medical Manufacturing
The Medical technology industry is likely to continue prioritizing manufacturing resilience, advanced automation, and dependable access to essential healthcare products. Companies are evaluating how domestic facilities, diversified suppliers, and digital manufacturing systems can support long-term operational stability.
BD’s plans reflect this broader focus on strengthening manufacturing infrastructure. If implemented successfully, additional capacity could help the company respond to customer needs while supporting the wider healthcare supply chain.
As the investment progresses, important developments to watch will include facility expansion milestones, production capacity, workforce growth, and the company’s plans for integrating new manufacturing technologies.
